In advanced NSCLC, the TG4010 vaccine, targeting MUC1 and interleukin-2, indicated enhanced progression-free survival (PFS) in the phase 2b/3 TIME trial, especially when used alongside first-line chemotherapy (180). The gene discussed is MUC1; the disease is non-small cell lung carcinoma.